Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model.
Animals
Blood Glucose
/ analysis
Body Weight
Collagen
/ metabolism
Diabetes Mellitus, Type 2
/ complications
Diabetic Cardiomyopathies
/ drug therapy
Diet, High-Fat
/ adverse effects
Fibrosis
Glycation End Products, Advanced
/ metabolism
Heart
/ drug effects
Insulin
/ blood
Irbesartan
/ pharmacology
Male
Matrix Metalloproteinases
/ metabolism
Myocardium
/ metabolism
Rats
Rats, Sprague-Dawley
Tissue Inhibitor of Metalloproteinase-2
/ metabolism
Irbesartan
Type 2 diabetes mellitus
advanced glycation end products and their receptor system
matrix metalloproteinases pathway
myocardial fibrosis
Journal
Experimental biology and medicine (Maywood, N.J.)
ISSN: 1535-3699
Titre abrégé: Exp Biol Med (Maywood)
Pays: England
ID NLM: 100973463
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
pubmed:
28
4
2019
medline:
27
5
2020
entrez:
28
4
2019
Statut:
ppublish
Résumé
There are about 425 million diabetes patients (20-79 years) in the world according to the International Diabetes Federation Diabetes Atlas - 8th Edition. The cardiovascular complication is one of the major causes of death in diabetes patients. Myocardial fibrosis is one of the serious pathological changes, so investigating the pathogenesis of myocardial fibrosis has the significant value. Our study aims to investigate the effect of Irbesartan (the angiotensin II receptor antagonist) on the changes of AGE-RAGE system and MMP family components, and analyzes the potential mechanisms in type 2 diabetes-induced myocardial fibrosis. Our results provide the theoretical base for better understanding the pathogenesis in type 2 diabetes-induced myocardial complication. It is useful for clinicians to select the effective therapeutic measures for treatment of type 2 diabetes-induced organ fibrosis.
Identifiants
pubmed: 31027433
doi: 10.1177/1535370219840981
pmc: PMC6545694
doi:
Substances chimiques
Blood Glucose
0
Glycation End Products, Advanced
0
Insulin
0
Tissue Inhibitor of Metalloproteinase-2
127497-59-0
Collagen
9007-34-5
Matrix Metalloproteinases
EC 3.4.24.-
Irbesartan
J0E2756Z7N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
612-620Références
Endocr Rev. 2004 Aug;25(4):543-67
pubmed: 15294881
Chin Med J (Engl). 2005 Jun 20;118(12):1040-4
pubmed: 15978215
Nephrol Dial Transplant. 2006 Jan;21(1):16-20
pubmed: 16280370
Drugs. 2007;67(7):997-1026
pubmed: 17488145
Diabetes. 2008 Jan;57(1):150-7
pubmed: 17928399
J Am Coll Cardiol. 2008 Jan 15;51(2):93-102
pubmed: 18191731
Ren Fail. 2010;32(7):871-9
pubmed: 20662702
FEBS J. 2011 Jan;278(1):28-45
pubmed: 21087458
Am J Med Sci. 2011 Mar;341(3):207-14
pubmed: 21326079
Microsc Res Tech. 2011 Nov;74(11):1018-23
pubmed: 21484942
Int J Cardiol. 2013 Jan 10;162(2):92-9
pubmed: 21704391
Pharmacol Res. 2012 Mar;65(3):297-302
pubmed: 22100460
Circ Res. 2012 May 11;110(10):1322-35
pubmed: 22474255
J Vasc Res. 2013;50(1):52-68
pubmed: 23172306
Circ Res. 2013 Jan 4;112(1):195-208
pubmed: 23287455
Fundam Clin Pharmacol. 2014 Jun;28(3):249-56
pubmed: 23600722
Curr Pharm Des. 2014;20(14):2395-402
pubmed: 23844818
Endocrinol Metab Clin North Am. 2014 Mar;43(1):41-57
pubmed: 24582091
Exp Clin Endocrinol Diabetes. 2014 May;122(5):277-80
pubmed: 24839222
World J Diabetes. 2014 Dec 15;5(6):860-7
pubmed: 25512788
Pharmacol Res. 2015 Mar;93:43-51
pubmed: 25617729
Clin Pharmacol Ther. 2015 Aug;98(2):145-61
pubmed: 25963811
J Diabetes Res. 2015;2015:656795
pubmed: 25973429
Cardiovasc Drugs Ther. 2015 Jun;29(3):243-55
pubmed: 25994830
Int J Clin Exp Pathol. 2015 May 01;8(5):5450-6
pubmed: 26191249
Oncotarget. 2015 Sep 22;6(28):26322-34
pubmed: 26314845
Hypertens Res. 2016 Apr;39(4):237-44
pubmed: 26657004
J Mol Cell Cardiol. 2016 Jan;90:84-93
pubmed: 26705059
J Card Fail. 2016 Oct;22(10):845-50
pubmed: 27018569
Adv Exp Med Biol. 2016;920:185-90
pubmed: 27535260
J Diabetes Res. 2016;2016:3834283
pubmed: 27547765
Trends Pharmacol Sci. 2017 May;38(5):448-458
pubmed: 28365093
Prog Mol Biol Transl Sci. 2017;147:75-100
pubmed: 28413032
Cardiovasc Pathol. 2017 Jul - Aug;29:37-44
pubmed: 28550760
Purinergic Signal. 2017 Dec;13(4):559-568
pubmed: 28840511
Oxid Med Cell Longev. 2017;2017:9257967
pubmed: 29129988
Oncotarget. 2017 Aug 24;8(58):98029-98039
pubmed: 29228671
Matrix Biol. 2018 Aug;68-69:167-179
pubmed: 29428229
Curr Med Chem. 2018 Mar 26;:null
pubmed: 29589527
Life Sci. 2018 Jul 15;205:184-192
pubmed: 29702126
Diabetes Care. 2018 Sep;41(9):2019-2025
pubmed: 30002196
Can J Physiol Pharmacol. 2019 Apr;97(4):246-256
pubmed: 30388374
Int J Biol Sci. 2018 Oct 31;14(13):1923-1934
pubmed: 30443195